capital-formation
(2)
Aditya Venugopal
Aditya Venugopal is the Chief Business Officer of Alentis Therapeutics, a clinical-stage Swiss biotech chasing first-in-class therapies aimed at claudin-1 for fibrosis and cancer. An immunologist turned dealmaker, he spent 15-plus years moving between the lab bench and the negotiating table: a Ph.D. in immunology from Weill Cornell, seven years in strategic life-science consulting, then senior roles at Intercept, VectivBio and Versanis Bio. He has a habit of being in the room when companies get acquired - VectivBio went to Ironwood, Versanis went to Eli Lilly - and he reunited with CEO Mark Pruzanski at Alentis after first partnering with him at Intercept.
Tom Morgan
Thomas W. Morgan is a 30-year private equity veteran who pioneered the GP stakes investing category when he founded Hycroft Capital in 2015, the first firm dedicated solely to minority, non-control investments in private equity management companies. His career arc spans First Boston, Bain Capital during its formative 1990s growth, and 15 years at New Mountain Capital (raising $15B+ AUM). After merging Hycroft into Magnetar Capital and co-founding Aviditi Advisors (acquired by Piper Sandler in 2024), he now manages Greylock Capital Partners, his family office with interests in franchise concepts, commercial real estate, and private investments, from Manhattan's Upper East Side.